7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

MaxCyte Presents Unprecedented Data Using Flow Electroporation for CHO-Based Transient Gene Expression to Achieve Gram Scale Antibody Production and Rapid Stable Cell Line Generation

May 20, 2013

Transient Gene Expression (TGE) Method Reporting Over 1 Gram/Liter Antibody Titersto be Presented at IBC’s 9th Annual Cell Line Development & Engineering Conference

Gaithersburg, Maryland - MaxCyte, Inc., the pioneer in scalable, high performance cell transfection systems, is hosting a series of events at IBC’s 9th Annual Cell Line Development & Engineering Conference being held May 20-22 in La Jolla, CA. During this cutting-edge conference on innovations for bioproduct development, MaxCyte will present breakthrough transient gene expression (TGE) data in a scientific podium presentation and detail unmatched novel antibody production capabilities in two technical posters. MaxCyte scientists will be available throughout the conference at Booth #12 to provide technical details on the use of flow electroporation for large scale transient gene expression and rapid stable cell line generation.


Dr. James Brady, Director of Technical Applications at MaxCyte, will present data on flow electroporation in a podium presentation entitled "Streamlining Antibody Development Using Large Scale, CHO Transient Gene Expression (TGE) followed by Rapid Production of CHO Stable Clones" on Tuesday, May 21, at 1:30 PM within a session dedicated to accelerating cell line and process development.


"Dr. Brady’s presentation demonstrates the unmatched performance of the MaxCyte Scalable Transfection Systemsto achieve antibody titers of over 1 gram/liter using transient gene expression in CHO cells. In addition, using the same technology, high yield stable cell lines can be identified within just 6-8 weeks," says Dr. Karen Donato, Executive Vice President of Global Business Development & Marketing at MaxCyte. "From the earliest phases of discovery and development, companies using the MaxCyte transfection platform now have a powerful tool to generate antibodies in CHO cells rapidly and reproducibly in meaningful quantities for identification and characterization."


MaxCyte will also present two scientific posters, both available for viewing throughout the conference. The first poster, entitled "CHO Transient Gene Expression (TGE) Optimization for Multi-Gram Level Antibody Production: Effects of Expression Construct, Post Transfection Cell Density and Feed Conditions" demonstrates a simple, optimized process to achieve antibody titers exceeding 1 gram/liter within 14 days of transfection. This poster is presented in collaboration with Vivalis, a key client and leading provider of innovative cell-based solutions to the pharmaceutical industry for the manufacture of vaccines and recombinant proteins.


The second poster, entitled "Bioproduction Using Large Scale Transient Transfection: From >1.2 grams/L Antibody Titers via Transient Gene Expression (TGE) to Rapid, High Yield Stable Cell Line Generation", presents data demonstrating the utility of the MaxCyte platform at multiple steps in antibody development including high yield antibody production via transient gene expression and rapid generation of stable cell lines in 6-8 weeks for later stage development and biomanufacturing.


"Companies are already realizing the benefits of streamlining progression from early to late stage development by using MaxCyte’s one-of-a-kind technology that brings together transient gene expression and rapid stable cell generation," says Douglas Doerfler, President, and CEO of MaxCyte. "MaxCyte flow electroporation is a truly enabling technology and we look forward to presenting our latest scientific findings to leaders in the development of biotherapeutics at the 9 th Annual Cell Line Development& Engineering Conference."







Please reload